TCGA-FD-A5C0-01A-11R-A28M-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 18.06833114
- os_event
- true
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.530
- G2M_CHECKPOINT+0.440
- PI3K_AKT_MTOR_SIGNALING+0.420
- PROTEIN_SECRETION+0.410
- MITOTIC_SPINDLE+0.360
- ANDROGEN_RESPONSE+0.290
- UNFOLDED_PROTEIN_RESPONSE+0.290
- ESTROGEN_RESPONSE_LATE+0.270
- P53_PATHWAY+0.270
- MYC_TARGETS_V1+0.210
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.340
- INTERFERON_GAMMA_RESPONSE-0.290
- KRAS_SIGNALING_DN-0.290
- PANCREAS_BETA_CELLS-0.260
- ANGIOGENESIS-0.250
- ALLOGRAFT_REJECTION-0.240
- HEDGEHOG_SIGNALING-0.230
- INFLAMMATORY_RESPONSE-0.150
- SPERMATOGENESIS-0.140
- IL6_JAK_STAT3_SIGNALING-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR13311180 | — | — | 0.796 |
| 2 | MNG1079 | — | — | 0.751 |
| 3 | TCGA-AC-A23H-01A-11R-A157-07 | — | C | 0.746 |
| 4 | MNG666 | — | — | 0.734 |
| 5 | TCGA-CF-A3MG-01A-11R-A20F-07 | — | — | 0.729 |
| 6 | MNG723 | — | — | 0.728 |
| 7 | TCGA-85-8351-01A-11R-2296-07 | — | cohortSQ1 | 0.728 |
| 8 | TCGA-E2-A14V-01A-11R-A12D-07 | — | C | 0.728 |
| 9 | TCGA-A2-A25E-01A-11R-A169-07 | — | B | 0.726 |
| 10 | TCGA-33-4586-01A-01R-1443-07 | — | cohortSQ2 | 0.724 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.530 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.440 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.420 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.410 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.360 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.290 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.290 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.270 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.270 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.210 | Inavolisib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.190 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.190 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.180 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.150 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.140 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.130 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.110 | Temsirolimus | — uncovered |
| PEROXISOME | 0.110 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.100 | Inavolisib | — uncovered |